



Joe Lombardo
Governor

NEVADA HEALTH AUTHORITY

Nevada Medicaid

4070 Silver Sage Drive
Carson City, NV 89701

NVHA.NV.GOV



Stacie Weeks, Director

Ann Jensen, Administrator

Drug Utilization Review Board Meeting Minutes

Date of Meeting: October 16, 2025

Name of Organization: The State of Nevada, Nevada Health Authority, Nevada Medicaid, Drug Use Review Board

Agenda Item	Record	Notes																								
1) Call to Order and Roll Call	It was announced the meeting is being recorded. Chairperson Jennifer Wheeler called the meeting to order at 1:06 p.m. on 10/16/2025. Chairperson Wheeler took the roll. <table> <tr> <th></th><th>Present</th><th>Absent</th></tr> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td><td>☒</td><td>☐</td></tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td>☒</td><td>☐</td></tr> <tr> <td>• Crystal Castaneda, MD</td><td>☐</td><td>☒</td></tr> <tr> <td>• Jessica Cate, Pharm.D.</td><td>☒</td><td>☐</td></tr> <tr> <td>• Dave England, Pharm.D.</td><td>☒</td><td>☐</td></tr> <tr> <td>• Brain Le, DO</td><td>☒</td><td>☐</td></tr> <tr> <td>• Jim Tran, Pharm.D.</td><td>☒</td><td>☐</td></tr> </table>		Present	Absent	• Jennifer Wheeler, Pharm.D., Chair	☒	☐	• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	• Crystal Castaneda, MD	☐	☒	• Jessica Cate, Pharm.D.	☒	☐	• Dave England, Pharm.D.	☒	☐	• Brain Le, DO	☒	☐	• Jim Tran, Pharm.D.	☒	☐	Nevada Medicaid Staff Present were as follows: • Brown, Antonio, Chief of Pharmacy & DME • Palomino, Bonnie, Pharmacy Services Manager • Flowers, Ellen, Social Services Program Specialist II • Cabrera, Donna, Program Officer I Prime Therapeutics Staff Present were as follows: • Mishra, Raj, Pharm.D., Clinical Account Manager • Deoliveira, Brittany, Pharm.D., Clinical Account Manager • Martinez, Chris, Sr. Business Analyst
	Present	Absent																								
• Jennifer Wheeler, Pharm.D., Chair	☒	☐																								
• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐																								
• Crystal Castaneda, MD	☐	☒																								
• Jessica Cate, Pharm.D.	☒	☐																								
• Dave England, Pharm.D.	☒	☐																								
• Brain Le, DO	☒	☐																								
• Jim Tran, Pharm.D.	☒	☐																								

		Managed Care Organization representatives present were as follows: • Bitton, Ryan, Pharm.D., Health Plan of Nevada • Beranek, Tom, Pharm.D., Silver Summit Health Plan • Tran, Jimmy, Pharm.D., Molina Healthcare • Izuora, Kodi, Pharm.D., Anthem The public attendee list is included as Attachment A. Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list’s accuracy is not assured.												
2) General Public Comment	Telephonic and web comment was called for, and the phone lines were opened.													
	No public comment was provided.													
3) Administrative														
a) For Possible Action: Review and Approve Meeting Minutes from July 31, 2025.	Vice-Chair Netochi Adeolokun moved to approve the minutes as presented, and Chairperson Wheeler seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td>☒</td><td>☐</td><td>☐</td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐	• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐	
	Yes	No	Abst.											
• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐											
• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐											

	• Crystal Castaneda, MD ☐ ☐ ☒ • Jessica Cate, Pharm.D. ☒ ☐ ☐ • Dave England, Pharm.D. ☒ ☐ ☐ • Brain Le, DO ☒ ☐ ☐ • Jim Tran, Pharm.D. ☒ ☐ ☐	
b) Status Update by DHCFP	Chief of Pharmacy Services Antonio Brown provided an announcement: Good afternoon, everyone. For the record, my name is Antonio Brown, Chief of Pharmacy Services for Nevada Medicaid. Thank you all for being here today and for your continued commitment to the health of our communities. I want to take a brief moment to update on the Single Preferred Drug List initiative. I am happy to share that the project remains on track for implementation on January 1st, 2026. We continue to collaborate closely with our Managed Care Partners. A few milestones are coming up for our focus on member communications. Our goal is to ensure that all the individuals that are going to be affected by this transition are well-informed and supported throughout the process. The primary objective, as a reminder for this initiative, is to reduce the administrative burden for both providers and recipients, simplify the prior authorization process and enhancements to care, and ultimately improve health outcomes for all Nevada Medicaid recipients. And as I always do, calling on our practitioners that may be joining us today. We have several open opportunities to serve on our board. If you're passionate about making a difference, we encourage you to get involved and help shape the future care of Nevada families and individuals. That concludes my updates, and thank you all for your time. I'll turn it over to Dr. Wheeler.	

4) Clinical Presentations		
a) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Hematopoietic/Hematinic Agents.		
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.	
ii) Presentation of utilization and clinical information.	Dr. Raj Mishra reviewed the proposed criteria presented in the binder for Hematopoietic/Hematinic Agents. • Dr. Ryan Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Tom Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Jimmy Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Kodi Izuora with Anthem, approved of the proposed criteria as presented.	
iii) Discussion by Board and review of utilization data.	Chairperson Wheeler asked if the Board Members had any comments. No comments were made.	

iv) Proposed adoption of updated prior authorization criteria.	Vice-Chair Adeolokun moved to approve the criteria as presented by Prime Therapeutics, and Board Member Brain Le seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Crystal Castaneda, MD</td><td>☐</td><td>☐</td><td>☒</td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Dave England, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Brain Le, DO</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Jim Tran, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐	• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐	• Crystal Castaneda, MD	☐	☐	☒	• Jessica Cate, Pharm.D.	☒	☐	☐	• Dave England, Pharm.D.	☒	☐	☐	• Brain Le, DO	☒	☐	☐	• Jim Tran, Pharm.D.	☒	☐	☐	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐																															
• Crystal Castaneda, MD	☐	☐	☒																															
• Jessica Cate, Pharm.D.	☒	☐	☐																															
• Dave England, Pharm.D.	☒	☐	☐																															
• Brain Le, DO	☒	☐	☐																															
• Jim Tran, Pharm.D.	☒	☐	☐																															
b) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Reblozyl (luspatercept-aamt) .																																		
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.																																	
ii) Presentation of utilization and clinical information.	Dr. Mishra reviewed the proposed criteria presented in the binder for Reblozyl. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Izuora with Anthem, approved of the proposed criteria as presented.																																	

iii) Discussion by Board and review of utilization data.	Chairperson Wheeler asked if the Board Members had any comments. No public comment was provided.																																	
iv) Proposed adoption of updated prior authorization criteria.	Board member Dave England moved to approve the criteria as presented by Prime Therapeutics, and Board Member Le seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Crystal Castaneda, MD</td><td>☐</td><td>☐</td><td>☒</td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Dave England, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Brain Le, DO</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Jim Tran, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐	• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐	• Crystal Castaneda, MD	☐	☐	☒	• Jessica Cate, Pharm.D.	☒	☐	☐	• Dave England, Pharm.D.	☒	☐	☐	• Brain Le, DO	☒	☐	☐	• Jim Tran, Pharm.D.	☒	☐	☐	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐																															
• Crystal Castaneda, MD	☐	☐	☒																															
• Jessica Cate, Pharm.D.	☒	☐	☐																															
• Dave England, Pharm.D.	☒	☐	☐																															
• Brain Le, DO	☒	☐	☐																															
• Jim Tran, Pharm.D.	☒	☐	☐																															
c) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for CGRP Receptor Inhibitor medications.																																		

i) <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. Public comment was provided by Dave Miley with Teva Medical Affairs.									
ii) Presentation of utilization and clinical information.	Dr. Mishra reviewed the proposed criteria presented in the binder for CGRP Receptor Inhibitor medications. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Izuora with Anthem, approved of the proposed criteria as presented.									
iii) Discussion by Board and review of utilization data.	Chairperson Wheeler asked if the Board Members had any comments. No comments were made.									
iv) Proposed adoption of updated prior authorization criteria.	Board Member England moved to approve the criteria as presented by Prime Therapeutics, and Vice-Chair Adeolokun seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><tr><td></td><td>Yes</td><td>No</td><td>Abst.</td></tr><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td>☒</td><td>☐</td><td>☐</td></tr></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐	
	Yes	No	Abst.							
• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐							

	• Netochi Adeolokun, Pharm.D., Vice-Chair ☒ ☐ ☐ • Crystal Castaneda, MD ☐ ☐ ☒ • Jessica Cate, Pharm.D. ☒ ☐ ☐ • Dave England, Pharm.D. ☒ ☐ ☐ • Brain Le, DO ☒ ☐ ☐ • Jim Tran, Pharm.D. ☒ ☐ ☐	
d) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for metabolic dysfunction-associated steatohepatitis (MASH) agents.		
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. Public comment was provided by Vignan Manne, gastroenterologist and hepatologist with UNLV School of Medicine. Public comment was provided by William Lam with Madrigal Pharmaceuticals.	
ii) Presentation of utilization and clinical information.	Dr. Mishra reviewed the proposed criteria presented in the binder for Wegovy and Rezdifra. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Izuora with Anthem, approved of the proposed criteria as presented.	

iii) Discussion by Board and review of utilization data.	Chairperson Wheeler asked if the Board Members had any comments. Vice-Chair Adeolokun and Board Member Jessica Cate provided comments.																																																					
iv) Proposed adoption of updated prior authorization criteria.	Vice-Chair Adeolokun moved to approve the criteria for Rezdiffra as presented by Prime Therapeutics with the addition of a statement to the step-edit requirement to include option from specialist justification if there is reason to expect Wegovy to be ineffective for recipient’s specific treatment. Chairperson Wheeler seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Crystal Castaneda, MD</td><td>☐</td><td>☐</td><td>☒</td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Dave England, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Brain Le, DO</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Jim Tran, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr></tbody></table> Vice-Chair Adeolokun moved to approve the criteria for Wegovy as presented by Prime Therapeutics, and Chairperson Wheeler seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Crystal Castaneda, MD</td><td>☐</td><td>☐</td><td>☒</td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐	• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐	• Crystal Castaneda, MD	☐	☐	☒	• Jessica Cate, Pharm.D.	☒	☐	☐	• Dave England, Pharm.D.	☒	☐	☐	• Brain Le, DO	☒	☐	☐	• Jim Tran, Pharm.D.	☒	☐	☐		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐	• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐	• Crystal Castaneda, MD	☐	☐	☒	• Jessica Cate, Pharm.D.	☒	☐	☐	
	Yes	No	Abst.																																																			
• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐																																																			
• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐																																																			
• Crystal Castaneda, MD	☐	☐	☒																																																			
• Jessica Cate, Pharm.D.	☒	☐	☐																																																			
• Dave England, Pharm.D.	☒	☐	☐																																																			
• Brain Le, DO	☒	☐	☐																																																			
• Jim Tran, Pharm.D.	☒	☐	☐																																																			
	Yes	No	Abst.																																																			
• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐																																																			
• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐																																																			
• Crystal Castaneda, MD	☐	☐	☒																																																			
• Jessica Cate, Pharm.D.	☒	☐	☐																																																			

	• Dave England, Pharm.D. ☒ ☐ ☐ • Brain Le, DO ☒ ☐ ☐ • Jim Tran, Pharm.D. ☒ ☐ ☐	
e) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Respirator and Allergy Biologics .		
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.	
ii) Presentation of utilization and clinical information.	Dr. Mishra reviewed the proposed criteria presented in the binder for Nucala. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Izuora with Anthem, approved of the proposed criteria as presented.	

iii) Discussion by Board and review of utilization data.	Chairperson Wheeler asked if the Board Members had any comments. No comments were made.																																	
iv) Proposed adoption of updated prior authorization criteria.	Board Member England moved to approve the criteria as presented by Prime Therapeutics, and Chairperson Wheeler seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Crystal Castaneda, MD</td><td>☐</td><td>☐</td><td>☒</td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Dave England, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Brain Le, DO</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Jim Tran, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐	• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐	• Crystal Castaneda, MD	☐	☐	☒	• Jessica Cate, Pharm.D.	☒	☐	☐	• Dave England, Pharm.D.	☒	☐	☐	• Brain Le, DO	☒	☐	☐	• Jim Tran, Pharm.D.	☒	☐	☐	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐																															
• Crystal Castaneda, MD	☐	☐	☒																															
• Jessica Cate, Pharm.D.	☒	☐	☐																															
• Dave England, Pharm.D.	☒	☐	☐																															
• Brain Le, DO	☒	☐	☐																															
• Jim Tran, Pharm.D.	☒	☐	☐																															
f) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Topical Immunomodulators .																																		
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. Public comment was provided by Jen Leung with Incyte Pharmaceuticals. Public comment was provided by Valeria Ng with Leo Pharma.																																	

ii) Presentation of utilization and clinical information.	Dr. Mishra reviewed the proposed criteria presented in the binder for Anzupgo. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Izuora with Anthem, approved of the proposed criteria as presented.																																	
iii) Discussion by Board and review of utilization data.	Chairperson Wheeler asked if the Board Members had any comments. No comments were made.																																	
iv) Proposed adoption of updated prior authorization criteria.	Vice-Chair Adeolokun moved to approve the criteria as presented by Prime Therapeutics, and Board Member Le seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Crystal Castaneda, MD</td><td>☐</td><td>☐</td><td>☒</td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Dave England, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Brain Le, DO</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Jim Tran, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐	• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐	• Crystal Castaneda, MD	☐	☐	☒	• Jessica Cate, Pharm.D.	☒	☐	☐	• Dave England, Pharm.D.	☒	☐	☐	• Brain Le, DO	☒	☐	☐	• Jim Tran, Pharm.D.	☒	☐	☐	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐																															
• Crystal Castaneda, MD	☐	☐	☒																															
• Jessica Cate, Pharm.D.	☒	☐	☐																															
• Dave England, Pharm.D.	☒	☐	☐																															
• Brain Le, DO	☒	☐	☐																															
• Jim Tran, Pharm.D.	☒	☐	☐																															

g) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Eohilia (budesonide oral suspension) .		
i) Public comment on proposed clinical prior authorization criteria.	No public comment was provided.	
ii) Presentation of utilization and clinical information.	Dr. Mishra reviewed the proposed criteria presented in the binder for Eohilia. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented with the recommendation to require submission of medical records to confirm diagnosis and broaden specialists to include immunologists. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Izuora with Anthem, approved of the proposed criteria as presented.	
iii) Discussion by board and review of utilization data.	Chairperson Wheeler agreed with recommendation to update specialists to include immunologists and asked if the Board Members had any additional comments. No additional comments were made.	

iv) Proposed adoption of updated prior authorization criteria.	Vice-Chair Adeolokun moved to approve the criteria as presented by Prime Therapeutics with the addition of immunologists to specialist list, and Board Member England seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Crystal Castaneda, MD</td><td>☐</td><td>☐</td><td>☒</td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Dave England, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Brain Le, DO</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Jim Tran, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐	• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐	• Crystal Castaneda, MD	☐	☐	☒	• Jessica Cate, Pharm.D.	☒	☐	☐	• Dave England, Pharm.D.	☒	☐	☐	• Brain Le, DO	☒	☐	☐	• Jim Tran, Pharm.D.	☒	☐	☐	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐																															
• Crystal Castaneda, MD	☐	☐	☒																															
• Jessica Cate, Pharm.D.	☒	☐	☐																															
• Dave England, Pharm.D.	☒	☐	☐																															
• Brain Le, DO	☒	☐	☐																															
• Jim Tran, Pharm.D.	☒	☐	☐																															
h) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Prolate (oxycodone/acetaminophen) .																																		
i) Public comment on proposed clinical prior authorization criteria.	No public comment was provided.																																	
ii) Presentation of utilization and clinical information.	Dr. Mishra reviewed the proposed criteria presented in the binder for Prolate. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria																																	

	as presented. • Dr. Izuora with Anthem, approved of the proposed criteria as presented.																																	
iii) Discussion by board and review of utilization data.	Chairperson Wheeler asked if the Board Members had any comments. No comments were made.																																	
iv) Proposed adoption of updated prior authorization criteria.	Board Member Jim Tran moved to approve the criteria as presented by Prime Therapeutics and Board Member Le seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Crystal Castaneda, MD</td><td>☐</td><td>☐</td><td>☒</td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Dave England, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Brain Le, DO</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Jim Tran, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐	• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐	• Crystal Castaneda, MD	☐	☐	☒	• Jessica Cate, Pharm.D.	☒	☐	☐	• Dave England, Pharm.D.	☒	☐	☐	• Brain Le, DO	☒	☐	☐	• Jim Tran, Pharm.D.	☒	☐	☐	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐																															
• Crystal Castaneda, MD	☐	☐	☒																															
• Jessica Cate, Pharm.D.	☒	☐	☐																															
• Dave England, Pharm.D.	☒	☐	☐																															
• Brain Le, DO	☒	☐	☐																															
• Jim Tran, Pharm.D.	☒	☐	☐																															
5) Board Requested Reports																																		
Opioid Utilization Reports: i) Opioid Trends ii) Top Members iii) Top Prescribers iv) Top Pharmacies	• Dr. Mishra presented opioid utilization reports. • Dr. Bitton presented opioid utilization reports. • Dr. Beranek presented opioid utilization reports. • Dr. Tran presented opioid utilization reports. • Dr. Izuora presented opioid utilization reports.																																	

Comments from Board Members regarding the Opioid Utilization Reports.	Chairperson Wheeler asked for comments from Board Members regarding Opioid Reports. The Board discussed possible optimization to the reports in the future.	
6) Standard DUR Reports: i) Top 10 Therapeutic Classes ii) ProDUR Paid Claims Savings Report iii) RetroDUR DUR Initiatives	• Dr. Mishra presented Standard DUR Reports. • Dr. Bitton presented Standard DUR Reports. • Dr. Beranek presented Standard DUR Reports. • Dr. Tran presented Standard DUR Reports. • Dr. Izuora presented Standard DUR Reports.	
7) Centers for Medicare and Medicaid Services (CMS) Annual Drug Utilization Review Surveys	• Dr. Mishra presented highlights for Fee-for-Service Annual DUR Survey • Dr. Bitton presented highlights for Health Plan of Nevada (HPN) Annual DUR Survey • Dr. Beranek presented highlights for SilverSummit Annual DUR Survey • Dr. Tran presented highlights for Molina Annual DUR Survey • Dr. Izuora presented highlights for Anthem Annual DUR Survey	
8) Physician Administered Drugs		
a) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Physician Administered Drugs.	aflibercept, Bavencio (avelumab), Beovu (brolucizumab-dbl), bevacizumab, Darzalex (daratumumab), Imfinzi (durvalumab), immune globulins IV, Jemperli (dostarlimab-gxly), Keytruda (pembrolizumab), Libtayo (cemiplimab-rwlc), Opdivo (nivolumab), paclitaxel albumin-bound, pemetrexed, ranibizumab, rituximab, immune globulins SC, Susvimo (ranibizumab), Tecentriq (atezolizumab), trastuzumab, Yervoy (ipilimumab)	

i) <u>Public comment</u> on proposed clinical prior authorization criteria.	No public comments were provided.																																	
ii) Presentation of utilization and clinical information	Dr. Victoria Facchini reviewed the proposed criteria presented in the binder for Physician Administered Drugs (PAD). • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Izuora with Anthem, approved of the proposed criteria as presented.																																	
iii) Proposed adoption of updated prior authorization criteria.	Vice-Chair Adeolokun moved to approve the criteria as presented by Prime Therapeutics, and Board Member England the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Crystal Castaneda, MD</td><td>☐</td><td>☐</td><td>☒</td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Dave England, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Brain Le, DO</td><td>☒</td><td>☐</td><td>☐</td></tr><tr><td>• Jim Tran, Pharm.D.</td><td>☒</td><td>☐</td><td>☐</td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐	• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐	• Crystal Castaneda, MD	☐	☐	☒	• Jessica Cate, Pharm.D.	☒	☐	☐	• Dave England, Pharm.D.	☒	☐	☐	• Brain Le, DO	☒	☐	☐	• Jim Tran, Pharm.D.	☒	☐	☐	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	☒	☐	☐																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	☒	☐	☐																															
• Crystal Castaneda, MD	☐	☐	☒																															
• Jessica Cate, Pharm.D.	☒	☐	☐																															
• Dave England, Pharm.D.	☒	☐	☐																															
• Brain Le, DO	☒	☐	☐																															
• Jim Tran, Pharm.D.	☒	☐	☐																															
9) Closing Discussion																																		

a) Public Comment	Telephonic and web comment was called for, and the phone lines were opened. No public comments were provided.	
b) Date and location of the next meeting.	Chairperson Wheeler stated the next meeting is scheduled for January 15, 2026. Location: Hilton Garden Inn, Reno Meeting adjourned at 3:01 pm	

Attachment A – Members of the Public in Attendance

Jen Leung	Hale, Amy	Nielsen, Mari
Abigail Banich	Gross, David	Robinson, Don
Lee Stout	Rassuchine, Bradley	Cheryl Donahue
Shawn Akey	Rianna White	Ann Marie O'Toole
Shannon Sturtevant	Valerie D Ng	
Lawson, Lindsey	Vignan Manne	
Moore, Kimberly A	Sabrina Schnur	
David Miley	Scott Tabot	
Thomas Deckelman	Roa, Ryan A	
Cade Grogan	Michael Pazirandeh	
Jenna Doerr	Selsor, Robin	
Faulkner, Kinga	Robin Wells	
William Lam	Jeana Colabianchi	
Pulver, Lisa	Maria Reyes	
Cadenhead, Alisa	Preisner, Eva	
Deborah G	Craig Sexton	

Attachment B – Submitted Written Comment

None Written Comments Submitted